Browse by Audience
MEMBER

Update Your Profile
Member Spotlights
Refer a Member: IASP Champions
Join a Special Interest Group (SIG)
Find a Chapter
Join Now

RESEARCHER

PAIN
PAIN Reports
Pain Research Forum
Papers of the Week
Webinars and Podcasts
Events

HEALTH CARE PROVIDER

Online Learning - PERC
Webinars & Podcasts
Curricula
Graduate Opportunities
Events

PATIENT & CAREGIVER

RELIEF News
Resources for Living with Pain
Global Alliance of Partners in Pain Advocacy (GAPPA)
Events

PARTNER

Support IASP
Sponsor an Event
Become a Partner

gy2022-1-3
I am a
IASP Logo
Home I AM A Search Login

Papers of the Week

Home / Publications / Pain Research Forum / Papers of the Week / Dupilumab shows long-term safety and efficacy in moderate-to-severe atopic dermatitis patients enrolled in a phase 3 open-label extension study.

< BACK TO ARCHIVE


Papers: 3 Aug 2019 - 9 Aug 2019


Human Studies, Pharmacology/Drug Development

PAIN TYPE:
Itch


2020 Feb


J Am Acad Dermatol


http://www.ncbi.nlm.nih.gov/pubmed/31374300?dopt=Abstract


82


2

Dupilumab shows long-term safety and efficacy in moderate-to-severe atopic dermatitis patients enrolled in a phase 3 open-label extension study.

Authors

Dupilumab shows long-term safety and efficacy in moderate-to-severe atopic dermatitis patients enrolled in a phase 3 open-label extension study.
Deleuran M, Thaçi D, Beck LA, de Bruin-Weller M, Blauvelt A, Forman S, Bissonnette R, Reich K, Soong W, Hussain I, Foley P, Hide M, Bouaziz J-D, Gelfand JM, Sher L, Schuttelaar MLA, Wang C, Chen Z, Akinlade B, Gadkari A, et al.
J Am Acad Dermatol. 2020 Feb; 82(2):377-388.
PMID: 31374300.

Abstract

Significant unmet need exists for long-term treatment of moderate-to-severe atopic dermatitis (AD).
Read This Paper